114 related articles for article (PubMed ID: 31074041)
1. Time-to-onset of treatment for hypertension and hyperlipidaemia in South African diabetes mellitus patients: A survival analysis using medicine claims data.
Obeng-Kusi M; Lubbe MS; Cockeran M; Burger JR
J Clin Pharm Ther; 2019 Oct; 44(5):701-707. PubMed ID: 31074041
[TBL] [Abstract][Full Text] [Related]
2. [Drug therapy of hyperglycemia and the prognosis of adult-onset diabetes mellitus].
Niskanen L; Uusitupa M; Laakso M
Duodecim; 1999; 115(10):1122-4. PubMed ID: 11877851
[No Abstract] [Full Text] [Related]
3. Coexisting Conditions among Children and Adolescents with Cancer in a Section of the South African Private Health Sector: Perspectives from Drug Utilization Data.
Otoo MN; Lubbe MS; Steyn H; Burger JR
J Epidemiol Glob Health; 2021 Mar; 11(1):105-116. PubMed ID: 33605112
[TBL] [Abstract][Full Text] [Related]
4. A cross-sectional analysis of the association between age and gender and prescribed minimum benefit chronic disease list conditions among South Africans with concomitant hypertension, diabetes and dyslipidaemia.
Burger J; Lubbe M; Serfontein J; Ellis S
Afr Health Sci; 2017 Mar; 17(1):88-98. PubMed ID: 29026381
[TBL] [Abstract][Full Text] [Related]
5. Duration of obesity is a risk factor for non-insulin-dependent diabetes mellitus, not for arterial hypertension or for hyperlipidaemia.
Pontiroli AE; Galli L
Acta Diabetol; 1998 Oct; 35(3):130-6. PubMed ID: 9840448
[TBL] [Abstract][Full Text] [Related]
6. Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes: The STIC2IT Cluster Randomized Clinical Trial.
Choudhry NK; Isaac T; Lauffenburger JC; Gopalakrishnan C; Lee M; Vachon A; Iliadis TL; Hollands W; Elman S; Kraft JM; Naseem S; Doheny S; Lee J; Barberio J; Patel L; Khan NF; Gagne JJ; Jackevicius CA; Fischer MA; Solomon DH; Sequist TD
JAMA Intern Med; 2018 Sep; 178(9):1182-1189. PubMed ID: 30083727
[TBL] [Abstract][Full Text] [Related]
7. Trends in antihypertensive and lipid-lowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
Gulliford MC; Charlton J; Latinovic R
J Hum Hypertens; 2005 Feb; 19(2):111-7. PubMed ID: 15361893
[TBL] [Abstract][Full Text] [Related]
8. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
Cooke CE; Lee HY; Tong YP; Haines ST
Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
[TBL] [Abstract][Full Text] [Related]
9. Impact of long-term antihypertensive and antidiabetic medications on the prognosis of post-surgical colorectal cancer: the Fujian prospective investigation of cancer (FIESTA) study.
Peng F; Hu D; Lin X; Liang B; Chen Y; Zhang H; Xia Y; Lin J; Zheng X; Niu W
Aging (Albany NY); 2018 May; 10(5):1166-1181. PubMed ID: 29846174
[TBL] [Abstract][Full Text] [Related]
10. Incidence of cardiovascular events in Italian patients with early discontinuations of antihypertensive, lipid-lowering, and antidiabetic treatments.
Corrao G; Zambon A; Parodi A; Merlino L; Mancia G
Am J Hypertens; 2012 May; 25(5):549-55. PubMed ID: 22278212
[TBL] [Abstract][Full Text] [Related]
11. [Arterial hypertension management in patients with type 2 diabetes].
Charpentier G; Genès N; Vaur L; Clerson P; Amar J; Guéret P; Cambou JP
Arch Mal Coeur Vaiss; 2002; 95(7-8):661-5. PubMed ID: 12365076
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Lan J; Zhao Y; Dong F; Yan Z; Zheng W; Fan J; Sun G
J Ethnopharmacol; 2015 Feb; 161():69-81. PubMed ID: 25498346
[TBL] [Abstract][Full Text] [Related]
13. Management of comorbidities in diabetics with renal cell carcinoma: past utilization and current outcomes.
Rabey JL; Yin J; Kublas TM; Mashtare T; Ceacareanu AC
J Pharm Pract; 2014 Feb; 27(1):31-9. PubMed ID: 23966283
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes.
Lowey A; Moore S; Norris C; Wright D; Silcock J; Hammond P
Pharm World Sci; 2007 Oct; 29(5):541-5. PubMed ID: 17394096
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
16. Treatment gaps for hypertension management in rural Canadian patients with type 2 diabetes mellitus.
Supina AL; Guirguis LM; Majumdar SR; Lewanczuk RZ; Lee TK; Toth EL; Johnson JA
Clin Ther; 2004 Apr; 26(4):598-606. PubMed ID: 15189757
[TBL] [Abstract][Full Text] [Related]
17. Are patients with dementia treated as well as patients without dementia for hypertension, diabetes, and hyperlipidaemia?
Müther J; Abholz HH; Wiese B; Fuchs A; Wollny A; Pentzek M
Br J Gen Pract; 2010 Sep; 60(578):671-4. PubMed ID: 20849694
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of drug usage and expenditure in a hospital diabetes clinic.
Wu SY; Lung BC; Chang S; Lee SC; Critchley JA; Chan JC
J Clin Pharm Ther; 1998 Feb; 23(1):49-56. PubMed ID: 9756112
[TBL] [Abstract][Full Text] [Related]
20. The impact of medication adherence on health outcomes for chronic metabolic diseases: a retrospective cohort study.
Han E; Suh DC; Lee SM; Jang S
Res Social Adm Pharm; 2014; 10(6):e87-e98. PubMed ID: 25088545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
